Introduction
Lennox-Gastaut Syndrome (LGS) is a rare and severe form of childhood epileptic encephalopathy characterized by the presence of multiple seizure types, generalized discharges with slow spikeand-wave complexes in the electroencephalogram, and mental deficiency or learning difficulties. [1] [2] [3] The pathophysiology of LGS is varied; in many cases, its aetiology is unknown, although some causes include brain abnormalities and prenatal or neonatal brain injury.
LGS accounts for 1-4% of all childhood epilepsies. 4 With a reported prevalence of 0.9 cases per 10,000 population across all age groups, 4, 5 LGS has been classified by the European Medicines Agency (EMEA) and US Food and Drug Administration (FDA) as an orphan disease since 2004. 6, 7 LGS is considered to be a catastrophic illness. In addition to the developmental disability experienced by patients with LGS, seizures are intractable and physically damaging, further interfering with the patient's intellectual and social development. Catastrophic epilepsies presenting during the childhood developmental stage halt cognitive and social development, leading to long-term effects. 8 LGS therefore represents a significant burden to both patients and their carers. Furthermore, while LGS-related healthcare costs have not been studied specifically, the direct lifetime costs for a patient in the US with intractable and frequent seizures is estimated to be almost $140,000 9 ; therefore, the economic burden per patient with LGS can be reasonably assumed to be significant. Seizures characteristic in LGS include tonic, atonic, atypical absence, myoclonic, clonic, and partial absence, with unclassified seizures also present. 10 Due to the difficulty in differentiating between tonic and atonic seizures, these are often combined in clinical studies of LGS and termed tonic-atonic seizures or 'drop attacks'. These drop attacks are the most physically damaging seizures causing recurrent injuries such as lacerations or head injuries due to falls. 10 As a result, many patients require constant supervision, often need protective headwear, or are confined to wheelchairs. The reduction in drop attack seizure frequency is therefore considered one of the most clinically significant outcomes for patients with LGS.
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LGS is a difficult-to-control condition, with considerable uncertainty regarding the optimum therapy 12 and little available guidance to assist specialist physicians in choosing appropriate antiepileptic drugs (AEDs). 13 There is currently no cure for LGS and, since existing treatments seldom offer complete control of seizures, treatment goals are to provide the best control of seizures, using the fewest AEDs, while limiting any adverse events. 14, 15 Moreover, the development of novel therapeutic agents for treating LGS is hindered by the absence of an appropriate animal model; as a result, treatment options for this devastating condition are severely limited. 13 Current first-line treatment involves the use of traditional AEDs (including valproate); none of which has been rigorously studied in controlled clinical trials in a population of patients with LGS. Treatment with these traditional AEDs rarely provides sufficient control of seizures, and newer AEDs are added to achieve a more effective combination therapy. 16 Newer AEDs, such as topiramate (TPM), lamotrigine (LTG), and felbamate, have demonstrated efficacy as adjunctive treatments for patients with LGS in randomized, placebo-controlled clinical trials. [17] [18] [19] In the UK, only TPM and LTG are licensed for the adjunctive treatment of patients with LGS. The use of adjunctive felbamate is limited to a 'named patient' basis and its use is restricted to last-line therapy due to the risk of life-threatening adverse events such as aplastic anemia and hepatitis. 20, 21 Newer AEDs are considered to offer an improved side effect profile relative to older agents; however, those commonly used for adjunctive use in LGS are not free from adverse events. Lifethreatening skin reactions such as Stevens-Johnson Syndrome have been associated with LTG 20 , while TPM is associated with impaired cognition 22 and weight loss. 23 The effects of TPM on cognition include impaired concentration, confusion, memory loss, psychomotor slowing, and speech disorder. 24 Since the impact of LGS on cognition is also well documented, 8 with patients often experiencing reduced alertness after seizures and being less responsive between seizures, medications that potentially compound the inherent cognitive disability seen in LGS would be undesirable to both caregivers and patients. Similarly, patients with LGS are often underweight and more prone to illness, as frequent seizures and constant physical activity utilize energy, resulting in both difficulties in eating and fatigue. Consequently, LGS treatments that induce a loss of appetite and weight loss, such as felbamate 21 and TPM, 23 can exacerbate the problems associated with being underweight, having a profound impact on patient well-being. Weight loss associated with TPM is particularly marked, to the extent that it has been extensively studied as a treatment for obesity. 25 Despite these undesirable adverse events, many patients with LGS often persist with their treatment due to the lack of alternative options. This situation highlights the need to develop new AEDs that are both effective in treating the multiple seizure types associated with LGS, and which also have an improved tolerability profile.
Rufinamide (RUF) is a structurally distinct AED licensed as adjunctive therapy for patients with LGS aged four years and over. RUF principally acts by prolonging the inactive state of sodium channels, inhibiting the firing of sodium-dependent action potentials. 26 A Phase III, double-blind, placebo-controlled clinical trial has shown RUF to be effective in reducing seizure frequency in patients with LGS. 15 RUF was significantly more effective than placebo in reducing total seizure frequency (32.7% reduction versus 11.7%, respectively, p = 0.0015) and drop attacks (42.5% reduction versus 1.4% increase, respectively, p = 0.0041). Furthermore, a significantly higher proportion of patients receiving RUF achieved greater than 50% reduction in total seizure frequency, compared with placebo (31.1% of patients versus 10.9%, respectively, p = 0.0045). This study also demonstrated that RUF was well tolerated, with the most commonly reported adverse events (including somnolence, vomiting, pyrexia, and diarrhea) being mild in intensity. 15 Importantly, a separate study also showed that RUF does not adversely affect cognition, even at high therapeutic doses. 27 As newer drugs are often more costly than existing therapies, and may offer only marginal benefits, it is important that decisionmakers are able to effectively assess the value of new treatments relative to existing therapies. This method of appraisal often poses challenges for orphan drugs, for which the price and cost-effectiveness estimates are generally high, 29, 30 and for which any economic analysis often relies heavily upon assumptions and evidence synthesis due to the paucity of appropriate clinical data. In addition, there may also be no validated disease-specific tools to assess health-related quality of life or, due to the rarity of orphan diseases, small clinical study samples make it difficult to make meaningful assessments of improvements in health-related quality of life with new interventions. The objective of this study was to evaluate the cost-effectiveness of RUF relative to TPM and LTG as adjunctive treatment for children with LGS in the UK.
Methods

Model structure
A Markov decision analytic model was developed to estimate the cost-utility of RUF versus TPM (or LTG) as adjunctive treatment for a hypothetical cohort of patients with LGS uncontrolled by up to three AEDs (Fig. 1) . In economic decision analytic models, mathematical relationships are used to define a series of possible consequences that would stem from the set of alternative options being evaluated. 31 Markov models are commonly used in health economic decision analyses, and are particularly well suited to modeling the progression of chronic diseases. For such analyses, the disease in question is divided into distinct and mutually exclusive health states, and a probability is assigned for the transition between the health states over a discrete time period, or cycle. Estimates of resource use and health outcome consequences are applied to each health state and transitions in the model. Subsequent running of the model over a large number of cycles generates an estimate of the long-term costs and benefits of a particular healthcare intervention. 31 In the present analysis, patients entering the model are administered RUF, TPM or LTG as an adjunctive treatment for a three-month time period. At follow-up, patients who have remained on their initial adjunctive therapy are classified into health states representing their response to adjunctive AED treatment:
WC75-drop attacks are really well controlled (!75% reduction in drop attacks from baseline). WC50-drop attacks are well controlled (!50% and <75% reduction in drop attacks from baseline). NC-non-responders where drop attacks are not well controlled (<50% reduction in drop attacks from baseline).
At the end of the first three months, patients may have also either switched to standard treatment due to adverse events or have died.
Patients then enter a maintenance phase of three-month cycles in which they can transition between health states (WC75, WC50, NC, and death). Patients who enter the NC state can switch to standard treatment, and then enter a separate Markov structure.
Patients on standard treatment receive a mix of AEDs as used in the placebo arm of the RUF clinical trial. 15 The health state descriptions focus on the impact of drop attacks on the daily life of children with LGS as these were deemed to be the most impactful and clinically relevant measures. Each health state was developed based on an extensive literature review, validation by expert physicians, and pilot interviews. 32 The seizure reduction thresholds applied to the health states are consistent with those used as standard practice in clinical studies of AEDs in LGS, 15, 17, 18 and are recognized by the EMEA as a valid endpoint for evaluating the efficacy of AEDs. 33 
Time horizon
LGS is a chronic, life-long disease and, ideally, an economic model should possess a lifetime horizon to capture lifetime costs and outcomes. A time horizon of three years was adopted in the base case analysis because the maximum follow-up was 36 months in the RUF study and 1225 days (approximately 40 months) in the TPM extension study. 15, 18 In order to accurately extrapolate beyond the data from randomized studies, it is important to have good evidence regarding the natural history of the disease, in terms of the defined health states. 34 While the long-term prognosis of patients with LGS is poorly documented, the limited available evidence suggests that seizure types and the clinical picture of LGS may evolve as children reach adulthood. Tonic seizures tend to become the dominant seizure type over time, while slow spike-and-wave patterns tend to resolve.
35,36 Therefore, extrapolation beyond five years (in the scenario analysis) was not deemed appropriate.
Data source: efficacy and safety
An extensive literature search identified three randomized, double-blind, placebo-controlled trials, one each for RUF, 15 TPM, 18 and LTG 17 for the management of LGS. These clinical trials were the only controlled studies of each drug in an LGS population identified by the literature search. In the absence of any head-to-head data directly comparing RUF, TPM, and LTG for treating LGS, Bayesian indirect or mixed-treatment comparisons, using a fixed-effects model, were used for comparator analysis to estimate the shortterm (three months) health state transition probabilities, and probabilities of discontinuation due to adverse events (Table 1) . Ideally, direct evidence from robust randomized controlled trials should be used to inform economic analyses; however, in the absence of direct head-to-head studies, indirect comparisons are considered appropriate to estimate the comparative effectiveness of different treatments. 37, 38 In the majority of cases, results generated using adjusted indirect comparisons have been shown to be consistent with the results of head-to-head randomized controlled trials. 39, 40 Adjusted indirect, or mixed-treatment comparisons are a generalization of a traditional pair-wise meta-analysis, including multiple pair-wise comparisons. This analysis preserves the randomized treatment comparison within trials, while combining available comparisons between treatments. 41 Due to the availability of only one study per drug treatment, a fixed-effects model was chosen instead of a random-effects model. The long-term transition probabilities for RUF therapy were derived from the clinical trial open-label extension data. 15 In the open-label extension phase of the TPM clinical study, primary clinical outcomes were defined as responses in the last three or six months since the patients had been receiving TPM, and hence were not directly comparable to outcomes in the RUF trial. In addition, the LTG trial did not have an open-label extension focusing on LGS patients only. Patients from the short-term, randomized LTG study entered a mixed group open-label extension with patients from other LTG trials, for which outcomes were not reported by patient type. Consequently, the TPM and LTG long-term transition probabilities were also based on the RUF study.
Data source: health state utilities
Since there were no appropriate published data reporting utility values for patients with LGS, a separate study was performed to elicit utilities for the LGS health states, among the UK general public. 32 Utilities were elicited primarily using the time trade-off (TTO) exercise, a method commonly used for utility generation in cost-effectiveness analyses. 42 
Data source: resource utilization and costs
This cost-utility study was performed from the perspective of the UK National Health Service (NHS) and Personal Social Services. Only direct healthcare costs, which included drug acquisition, NHS resource use, inpatient stay, diagnostic procedures, personal social services, and the costs associated with treating adverse events, were utilized. Drug acquisition costs for RUF, TPM, and LTG, together with the cost of background standard treatments and standard treatment after switching, were calculated based on mean daily dose and costs presented in the British National Formulary 54th Edition 43 ( Table 2) . Estimates of healthcare resource use were obtained through a survey of physicians specializing in pediatric epileptology. Medical resource costs, and costs due to adverse events, were calculated according to Table 1 Patient distribution probability across model transition states and probability of patients discontinuing treatment due to adverse events, after three months. (Table 3) .
Adverse events were assumed to occur only within the first three months of treatment initiation; therefore, these costs were limited to this period. In line with UK Health Technology Assessment (HTA) requirements, an annual discount rate of 3.5% was used for both costs and benefits.
Outcomes
The outcome parameters of the present analysis were QALYs, drug acquisition costs, other medical costs (i.e., those associated with NHS contacts, inpatient stays, personal social services, and diagnostic procedures), costs associated with adverse events, and total costs. From these outcomes cost-effectiveness was estimated using the incremental cost per QALY and net monetary benefit (NMB) of RUF relative to each comparator.
Assumptions
The following assumptions were made in the cost-utility analysis:
The clinical trial populations within the three pivotal trials of RUF, 15 TPM, 18 and LTG 17 were representative of patients with
LGS in clinical practice.
In the absence of head-to-head data comparing the three drug treatments, Bayesian mixed-treatment comparisons accurately represented the comparative efficacy and safety of RUF, TPM, and LTG. Transition probabilities, derived from the period between three months and six months of the RUF trial, accurately represented the movement of patients in the maintenance phase of the model. 
Base case analysis
The base case analysis primarily estimated the incremental cost-utility ratio of adjunctive RUF relative to TPM over a threeyear horizon. The base case analysis also estimated the incremental cost-utility ratio of RUF relative to LTG. The cost-utility analysis of RUF versus LTG was secondary due to the paucity of comparable efficacy data for LTG.
Sensitivity analyses
Probabilistic sensitivity analysis was used to capture the uncertainty in the input parameters. Uncertainty surrounding input parameter estimates, such as efficacy, safety, utilities, and costs, are characterized by the limitations or absence of evidence available to inform input parameters. Limitations of available empirical studies may result from sampling problems (e.g., if not all patients were measured), and this uncertainty can be expressed as standard errors or 95% confidence intervals. In the probabilistic sensitivity analysis of the present economic model, uncertainty in efficacy, safety transition probabilities, utilities, and discontinuation were expressed as beta-distributions, while uncertainties in cost data were expressed as gamma-distributions.
A distribution of the incremental costs and benefits (QALYs) was determined by sampling a value from each input parameter distribution, calculating the results with the model, then repeating this process 1000 times. The results were presented with a point estimate and 95% uncertainty intervals, as well as a jointdistribution of incremental costs and QALYs on a cost-effectiveness plane, illustrating the uncertainty surrounding the estimates of incremental costs and QALYs. A cost-effectiveness plane is divided into four quadrants. The south-east quadrant represents instances where the intervention is more effective and less costly than the comparators (dominates), with the opposite situation in the northwest quadrant, where the intervention is more costly and less effective than comparators (dominated). The north-east quadrant represents interventions that are more costly yet more effective, while the south-west quadrant represents less effective and less costly interventions. 46 Cost-effectiveness acceptability curves are also constructed to show the probability that an intervention is cost-effective compared with an alternative, for a given range of WTP values. 46 One-way sensitivity analysis was used to test the uncertainty of model parameters when varied by AE20%.
Scenario analysis
Uncertainty surrounding scenario judgments relates to assumptions made in economic analyses for input data that cannot be observed empirically. These include drug unit costs, discount rates, and the time horizon considered. Uncertainty of this nature is analyzed by means of multiple scenario analyses, where a separate probabilistic analysis is performed for each scenario.
The primary base case scenario estimated the incremental costutility ratio of RUF relative to TPM and LTG, when used adjunctively to standard care with a three-year time horizon. In this primary scenario, both costs and benefits were discounted at a rate of 3.5%. Alternative scenarios investigated were:
A time horizon of one year and five years. Applying 0% and 6% discounting to both costs and benefits.
Results
Base case analysis
Over the three-year time horizon, a greater proportion of patients are assumed to achieve WC75 status with RUF treatment, compared with TPM or LTG. On average, patients remained on RUF for 1.67 years before switching to standard treatment, compared with 1.64 and 1.69 years for TPM or LTG, respectively. After three years, the discounted cumulative drug costs were highest for RUF, although the medical resource costs and costs of treating adverse events are expected to be lowest with this agent. Overall, RUF would result in the highest costs over the three-year time horizon (Table 4) .
The total cumulative costs and associated QALYs for RUF, TPM, and LTG, are shown in Table 4 . The corresponding incremental cost per QALY for the primary (RUF versus TPM) and secondary (RUF versus LTG) analyses are also presented in Table 4 .
Probabilistic sensitivity analysis
In the cost-effectiveness plane, the results scatter predominantly in the north-east quadrant, indicating that RUF is more effective, but more expensive, than TPM and LTG (Fig. 2) . Some points, however, appear in the north-west and south-east quadrant, suggesting that in some instances RUF is either dominated by, or itself dominates, TPM and LTG. The wide distribution of the results in the cost-effectiveness plane thus reflects the uncertainty around the point estimate. Analysis of the uncertainty was determined by sampling a value for each input parameter distribution, calculating the results with the model and repeating the process 1000 times. Analysis of the costeffectiveness estimate revealed that over 90% of the uncertainty around costs and QALYs were attributed to the transition probabilities of initial treatment (Fig. 3) . Other medical costs accounted for 7-10% of the uncertainty in costs, while utilities explained approximately 1% of the uncertainty in QALYs, but had little or no effect on costs.
The probability of RUF being cost-effective compared to TPM and LTG for different WTP thresholds is indicated by the costeffectiveness acceptability curve (Fig. 4) . At a WTP threshold of £20,000, the probability that RUF is more cost-effective than TPM or LTG is 52% and 8%, respectively. If a WTP of £30,000 is considered, the corresponding probability of RUF being more costeffective than TPM or LTG rises to 65% and 15%, respectively. 
One-way sensitivity analysis
The results of the model were most sensitive to changes in the model health state transition probabilities during RUF, TPM, and LTG treatment. Fig. 5 shows the RUF versus TPM model input parameters which, when varied by AE20%, led to a !10% change in the ICER. The model was not sensitive to any of the remaining model inputs, which when varied had relatively little impact on the ICER. Fig. 6 shows the sensitivity of the RUF versus LTG model when input variables were varied by AE20% which resulted in a !10% change in the ICER. Varying any remaining model inputs had relatively little impact on the ICER estimate. In both the RUF versus TPM, and RUF versus LTG analyses, the ICER was especially sensitive to the transition probabilities of patients achieving and maintaining WC75 status (Figs. 5 and 6, respectively) .
Scenario analysis
Further analyses were performed to investigate the effects of using alternative, time horizon, and discounting of both costs and benefits. The same incremental costs were used for each scenario analysis. Alternative scenarios under different time horizons and discount rates provided comparable results as the base case analysis. Under each of the different scenarios the ICER of RUF versus TPM remained below £29,000 and ICER of RUF versus LTG remained over £154,000.
Discussion
In patients with LGS, whose disease is uncontrolled by up to three AEDS, the incremental cost per QALY gained with RUF therapy versus TPM or LTG, was £20,530 and £154,831, respectively. Therefore, RUF may be considered to be a costeffective alternative to TPM as adjunctive treatment for patients with LGS in the UK. In addition, in view of the importance of patient choice and equity of access in such a rare and devastating condition, RUF should be considered an effective alternative to inexpensive LTG, for the adjunctive treatment of LGS.
There are very few treatment options available for LGS, with current therapies being described as 'difficult and disappointing'. 47 Current treatments have variable efficacy and safety/tolerability profiles in different patients, making them more appropriate for some patients than others. As a result, providing treatment choice for LGS is paramount.
Model-based health economic studies are commonly used to integrate clinical efficacy and safety data, with estimates of resource utilization and productivity data, to assess the costeffectiveness of novel interventions. However, for epilepsy in general, cost-effectiveness analyses for newer AEDs are constrained by a paucity of data, and the assessment of newer AEDs for pediatric epilepsies is no exception. In the only published costeffectiveness analysis of newer AEDs focusing on children aged 3-18 years, with a diagnosis of partial epilepsy with or without primary generalization, it was concluded that insufficient were data available to accurately estimate the trade-offs between newer and older AEDs. 48 Only two studies have assessed the cost-effectiveness of interventions for LGS. The first is a study assessing the costeffectiveness of RUF in the treatment of LGS from a UK societal perspective. Benefits were measured in terms of the cost per 1% increase in successfully treated patients (defined as patients with >50% reduction in the frequency of total seizures). RUF was compared with TPM, LTG, and standard treatment in an individual patient simulation model over a three-year horizon, reporting a cost per 1% increase in successfully treated patients of £128 and £2151 when RUF was compared with TPM and LTG, respectively. 49 Relative to standard treatment, RUF treatment resulted in a significantly higher proportion of successfully treated patients; therefore, the incremental cost-effectiveness of RUF compared with standard therapy was £85 per 1% increase in successfully treated patients. 49 The second cost-effectiveness study estimated the cost per single seizure reduction following surgical vagal nerve stimulation. 50 This study was performed in patients with LGS (aged 7-18 years), from a Dutch perspective, over a 24-month horizon and showed that the cost required to prevent one seizure was s16.93. 50 Although this is not directly comparable to the measures of cost-effectiveness in the present study, the high number of seizures experienced by LGS sufferers suggests the cost required to reduce a patient's seizures by 50% over a three-year time horizon would be relatively high.
Similarly, relatively few studies were available to determine the effectiveness of treatments for patients with generalized seizures in an HTA performed for NICE. 51 It was reported that newer AEDs used adjunctively were more effective, yet more costly than continuing with existing monotherapy treatments, and that adjunctive therapy with newer AEDs may be cost-effective at a WTP threshold of greater than £20,000 per QALY. Valproate and LTG were shown to have similar clinical benefits when used as monotherapy, and adjunctive TPM was deemed to be cost-effective with an ICER of £34,500, relative to continuing with standard monotherapy.
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There are also relatively few cost-effectiveness analyses reporting a cost per QALY for newer AEDs for adjunctive therapy in adults with refractory partial epilepsy. [52] [53] [54] [55] In the economic analysis reported by Messori et al., the cost per QALY gained following the adjunctive use of LTG (500 mg/day) relative to placebo in patients with refractory epilepsy was estimated to be $41,000. 53 This economic analysis used a lifetime horizon and considered direct costs derived from an analysis of the lifetime costs of US patients with epilepsy diagnosed in 1990, 56 and clinical data were obtained from a six-month, randomized, double-blind, placebo-controlled study of patients with refractory partial seizures. 57 Maltoni and Messori investigated the lifetime cost-effectiveness of TPM (200 mg/day), as adjunctive therapy, relative to placebo, in patients with refractory epilepsy uncontrolled by up to two AEDs. The cost per QALY gained estimated in this analysis was £21,353, 52 using outcome data derived from a subgroup analysis of a 12-week, randomized, placebo-controlled study. 58 The analysis used direct costs estimated in a UK setting from a societal perspective. A secondary analysis, using an identical model to that used for LTG by Messori et al., 53 considered two simulated cohorts Finally, the analysis of adjunctive pregabalin (300 mg/day) in patients with refractory epilepsy uncontrolled on at least one AED estimated the cost-effectiveness over a one-year horizon in a US setting. This analysis used a Markov model with clinical data derived from the unpublished pregabalin clinical trials program. The results showed that, relative to standard treatment, the cost per QALY gained was estimated as $52,983. 54 The results from these economic studies are not directly comparable to the results from the present analysis of RUF for treating LGS. For instance, health states and treatment outcomes are not comparable as treatment outcomes in refractory partial epilepsy are often described in terms of seizure-free days, whereas seizure freedom is rarely achieved with LGS treatments. Moreover, inconsistent time horizons, assumptions, and modeling approaches adopted across the different studies further prohibit comparisons with our analysis.
The present economic analysis has a number of strengths and limitations which should be noted and considered when interpreting this analysis. In the absence of appropriate published quality of life data or utility estimates for LGS health states, a separate study was specifically designed to elicit utilities for the health states of children with LGS from the UK general public. 32 The health states used in the present analysis
were not related to specific treatments and designed to accurately reflect achievable treatment thresholds applied in
LGS clinical studies. Compared with other, broader types of epilepsy, there are very few placebo-controlled studies of LGS interventions. This is illustrated by the identification of only one randomized, placebo-controlled study evaluating the efficacy in LGS, for each of the three treatments assessed in the present analysis. Due the absence of comparative clinical studies, Bayesian, mixed-treatment comparisons were used to indirectly assess the comparative efficacy and safety of RUF, TPM, and LTG. Providing there are no known sources of bias, this approach has sound statistical grounds for estimating comparative efficacy in the absence of direct head-tohead data. Bias can occur if there is an association between any differences in patient characteristics and treatment effect. 41 The studies used for indirect or mixed-treatment comparisons in the present analysis were similar regarding study design and patient characteristics: the most noticeable difference being that patients in the TPM study were receiving one to two AEDs (perhaps indicating less severe disease), while the patients in the RUF and LTG studies were receiving up to three concomitant AEDs. However, for RUF, no association was found between the number and type of AEDs received and the results of the primary efficacy analysis. 59 Therefore, the differences in concomitant AED use was not expected to represent a significant source of bias favoring RUF in indirect efficacy and safety estimations used in the present analysis. When using patient populations from clinical studies to inform health economic analyses, it is often assumed that study patient populations are representative of populations in clinical practice. This is a common assumption, with recognized limitations as efficacy in clinical studies may not necessarily translate into reallife effectiveness. 60 However, as LGS is a rare condition, an expert panel was consulted to determine relatively broad LGS diagnostic criteria and study inclusion criteria in order to enable sufficient patient recruitment in each study. As a result, it is unlikely that this assumption would pose a significant limitation in the present economic analysis, especially since a recent observational study has demonstrated that RUF shows comparable effectiveness in a real-life setting. 61 For the maintenance phase of the model, transition probabilities among health states for RUF treatment were derived from the period between three and six months in the RUF clinical study. These transition probabilities were assumed to predict the longer term course of LGS throughout the maintenance period. This assumption was required as the later phase of the RUF study 15 had insufficient patient numbers upon which to base an accurate estimate. This is viewed as a valid assumption since the RUF openlabel extension did not report evidence to suggest any tolerance to RUF, and the proportion of patients achieving 50% and 75% reductions in seizure frequency remained comparable. The longterm transition probabilities for RUF were also assumed to appropriately describe the transition of patients receiving TPM and LTG within the model. This is a conservative assumption as three-month transition probabilities suggest that RUF is likely to result in fewer seizures than TPM or LTG. All models are simplifications of reality; it is not possible to include all ramifications of a particular treatment. Therefore, the analysis only accounted for the occurrence of adverse events within the first three months following the initiation of any AED therapy. This is because the majority of treatmentlimiting adverse events tend to occur within the first three months of treatment initiation, normally resulting in treatment switching.
The present analysis used mean AED doses reported by clinicians, and those used in clinical studies, to calculate drug costs. It is assumed that this represents the average consumption of the study drugs, and that any reduced costs due to the lower starting doses would be cancelled out by those patients receiving higher than average doses. It was also assumed that daily doses of RUF and concomitant AEDs, as well as other resource use, remained the same in every three-month cycle. These are conservative assumptions for RUF since the open-label extension indicated that there was a decrease in the total daily dose of concomitant AEDs for approximately half of the patients following 30 months of adjunctive treatment with RUF. Furthermore, dose titration was also assumed not to result in additional resource use; this may also be considered a conservative assumption given the differences in the longer recommended titration schedules for TPM 62 and LTG. 63 An expert physician survey provided an estimate of resource use in place of a direct survey of UK clinical practice. This method may introduce a source of subjective bias, as ideally costs due to resource use should be based on actual data obtained in a prospective study. However, due to constraints owing to the rare nature of the disease, a panel of expert physicians was considered to provide the best estimate of resource for the present costeffectiveness analysis.
It was also assumed that concomitant, non-comparator AED utilization was comparable across all studies, based on the placebo arm of the RUF clinical study. 15 It must be noted that due to the commercial availability of TPM and LTG, some patients in the treatment and placebo arms of the RUF clinical study received TPM and/or LTG as concomitant AEDs. However, in the model, concomitant use of any comparator drug was removed from cost calculations to avoid double-counting. Furthermore, the impact of LGS treatment on premature death, costs for parents and caregivers, and other indirect costs were not taken into account in the analysis. Indirect costs form a substantial part of the total costs of LGS; therefore, costs of all three treatments may have been underestimated. There is no separate, published long-term efficacy and safety study for LTG in a population of LGS patients. Furthermore, in the short-term study !75% responder rates were not reported. 17 However, given the importance of LTG as an existing adjunctive therapy for LGS, and therefore as a comparator in this economic analysis, a !75% response rate was estimated. As a result, the ICER of RUF relative to LTG is sensitive to the probability of patients receiving RUF achieving the WC75 health state. Finally, the model may underestimate the incidence of adverse events from TPM and LTG use due to the limited information on adverse events reported in the available clinical studies. 17, 18 The use of LTG is associated with the development of serious rash or Stevens-Johnson Syndrome. 64 Rash is often reported as 'general rash'; however, in the LTG study, rash led to the withdrawal of two patients: one patient was hospitalized and the other was diagnosed with Stevens-Johnson Syndrome. 17 A further patient, who was also receiving cephalosporin for pneumonia, was also reported to have developed Stevens-Johnson Syndrome shortly after LTG had been withdrawn. However, in the present model, medical resource use and costs relating to general rash were applied, rather than costs associated to more serious rash or Stevens-Johnson Syndrome. Therefore, this may underestimate the true costs of adverse rash events associated with LTG treatment.
Conclusions
The cost-effectiveness of RUF, relative to TPM and LTG, in the treatment of LGS has been modeled as robustly as possible within the constraints of the available data. Given the underlying assumptions and current evidence available, the economic analysis described demonstrates that RUF is cost-effective relative to TPM as adjunctive therapy in LGS. Although, in the comparison with generic LTG, the cost-effectiveness ICER of RUF exceeds the accepted UK thresholds, there is a higher level of uncertainty around this estimate. Given the status of LGS as an orphan disease, and the limited treatment choices available for children with this serious condition, RUF should be considered a feasible, effective, and cost-effective treatment option.
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